London, 11 December 2015: Technavio, the independent tech-focused global research firm, has published a report on the global hepatitis drugs market 2015-2019, which is predicted to grow at a CAGR of 16.6% during the forecast period of 2014-2019.
The pipeline for hepatitis drugs is quite robust, with multiple new drugs across various stages of clinical development. Pipeline drugs with superior efficacy and safety are expected to have a significant impact on market growth post-launch.
“The global hepatitis drugs market in emerging countries such as India, Brazil, China, and Russia is expected to grow at a rapid pace during the forecast period owing to an increase in patient population and public awareness about hepatitis,” says Faisal Ghaus, Vice President of Technavio.
“The global hepatitis drugs market is growing rapidly due to the arrival of pediatric combination vaccines that achieve higher seroconversion rates in high-risk adults. These vaccines protect against multiple causative agents and thereby reduce the costs.”
Key Market Drivers
- Unmet medical needs
- Increase in awareness
- Advent of next-generation DAAs
- Emergence of IFN-free therapies
- Increase in injection drug users
Key Market Trends
- Increase in collaborations, mergers, and acquisitions
- Focus on emerging markets
- Emergence of combination vaccines
Key Market Vendors
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Roche
- Vertex
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
If you are interested in more information on this topic and our upcoming research on the Global Hepatitis Drugs Market 2015-2019, please send an e-mail to media@TechNavio.com.
Follow us on Twitter @ Technavio
Like us on Facebook
Follow us LinkedIn
Connect with us on Google+
